-- 
Israeli Stocks: Ceragon, Gulliver, Hadasit, Pluristem, Teva

-- B y   S u s a n   L e r n e r
-- 
2011-06-19T15:04:41Z

-- http://www.bloomberg.com/news/2011-06-19/israeli-stocks-ceragon-gulliver-hadasit-pluristem-teva.html
Israel ’s TA-25 Index gained for a
second day, increasing less than 0.1 percent to 1,206.22 at the
4:30 p.m. close in  Tel Aviv . Investors traded about 1.1 billion
shekels ($321 million) in shares and convertible securities.  The following stocks rose or fell. Symbols are in
parentheses.  Ceragon Networks Ltd. (CRNT)   jumped 4.6 percent, the
most since March 31, to 37.95 shekels. Brigantine Advisors
increased its recommendation on the maker of wireless-networking
systems to “buy” from “hold” and set a share-price estimate
of $14.  Gulliver Energy Ltd. (GLVR IT) surged 8.2 percent to 1.34
shekels, the highest level since August 2007. The oil and gas
explorer will receive a 7.5 million-shekel loan from  Molodan
Ltd. (MLDN)  . Molodan was unchanged at 2.828 shekels.  Hadasit Bio-Holdings Ltd. (HDST)   gained 4.2 percent to
1.003 shekel, the highest since May 12. The developer of
diagnostic and treatment products signed an American depositary
receipt agreement with the Bank of New York Mellon Corp.  Pluristem Therapeutics Inc. (PSTI)   increased the most
since May 17, advancing 6.9 percent to 10.19 shekels. Dawson
James Securities Inc. initiated coverage of the developer of
cell-therapy products with a “buy” recommendation and $5
share-price estimate.  Sialo Technology Israel Ltd. (SALO)   soared to the
highest since June 1, jumping 18 percent to 0.724 shekel. The
developer of oral-surgery equipment signed an agreement for the
distribution of its products in  India .  Teva Pharmaceutical Industries Ltd. (TEVA)   fell the most
since July 2010, declining 4.8 percent to 162.50 shekels. The
U.S.-traded shares of the world’s largest maker of generic drugs
retreated to $47.49 (162.96 shekels) over the last two trading
days. A U.S. district court on June 17 ordered a July 11 start
date for a trial on Teva’s multiple-sclerosis medicine Copaxone.  To contact the reporter on this story:
Susan Lerner in Jerusalem at 
 slerner2@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  